This is a preview of subscription content, log in via an institution to check access.
Notes
The study was financially supported by Bayer B.V.
Reference
Peters ML, et al. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer. Applied Health Economics and Health Policy : 2 Sep 2017. Available from: URL: http://dx.doi.org/10.1007/s40258-017-0350-x
Rights and permissions
About this article
Cite this article
Radium-223 less costly option in mCRPC in the Netherlands. PharmacoEcon Outcomes News 786, 31 (2017). https://doi.org/10.1007/s40274-017-4321-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4321-0